Showing results (31-40 of 61) with videos related to
Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patientsNaoko Takebe, Xiangfei Cheng, Suhlan Wu, et al.British Journal of Haematology|May 20, 2016
A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysisNeeraj Gupta, Michael J Hanley, R Donald Harvey, et al.Experimental Hematology|January 25, 2003
Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioningChoon Kee Lee, Ashraf Badros, Bart Barlogie, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248Steven P Treon, Zachary R Hunter, Jeffrey Matous, et al.Journal of the National Cancer Institute|April 5, 2014
Multiple myeloma in the very old: an IASIA conference reportSascha A Tuchman, Gary R Shapiro, William B Ershler, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myelomaAshraf Badros, Angelika M Burger, Sunita Philip, et al.Journal of Clinical Pharmacology|December 8, 2016
Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple MyelomaYing Ou, Sameer Doshi, Anh Nguyen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemiaIrene M Ghobrial, Fangxin Hong, Swaminathan Padmanabhan, et al.Transplantation and Cellular Therapy|June 26, 2026
Predictors of Rehabilitation Utilization After CAR T-Cell TherapyHanan Alharthy, Abdulaziz Abu-Haimed, Renu E Thomas, et al.American Journal of Hematology|July 24, 2010
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström MacroglobulinemiaIrene M Ghobrial, Wanling Xie, Swaminathan Padmanabhan, et al.Pageof 7